Guidelines have been issued regarding proper anticoagulant and antiplatelet treatment of patients who undergo endoscopic procedures. Medscape Medical News
Adding valsartan to therapy in high-risk hypertensive patients reduced the risk of cardiovascular events more than conventional non-ARB treatment in both the primary- and secondary-prevention setting, according to an analysis from KYOTO HEART, while JIKEI HEART investigators suggest a benefit with valsartan in coronary artery disease patients. Heartwire
